Global Live Attenuated Vaccines Market Growth 2023-2029

Global Live Attenuated Vaccines Market Growth 2023-2029

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).

LPI (LP Information)' newest research report, the “Live Attenuated Vaccines Industry Forecast” looks at past sales and reviews total world Live Attenuated Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Live Attenuated Vaccines sales for 2023 through 2029. With Live Attenuated Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live Attenuated Vaccines industry.

This Insight Report provides a comprehensive analysis of the global Live Attenuated Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live Attenuated Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Live Attenuated Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live Attenuated Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live Attenuated Vaccines.

The global Live Attenuated Vaccines market size is projected to grow from US$ 25370 million in 2022 to US$ 38990 million in 2029; it is expected to grow at a CAGR of 38990 from 2023 to 2029.

Examples of live attenuated) vaccines include: Viral: measles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; Bacterial: BCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Live Attenuated Vaccines market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Bacterial
Viral

Segmentation by application
Hospitals
Clinics
Research Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India

Key Questions Addressed in this Report

What is the 10-year outlook for the global Live Attenuated Vaccines market?

What factors are driving Live Attenuated Vaccines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Live Attenuated Vaccines market opportunities vary by end market size?

How does Live Attenuated Vaccines break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.